Abstract
The Death Domain Fold superfamily of evolutionarily conserved protein-protein interaction domains consists of 4 subfamilies: the death domain, the death effector domain, the caspase recruitment domain, and the PYRIN domain. Interaction of Death Domain Fold containing proteins modulates the activity of several downstream effectors, such as caspases and transcription factors. Recent studies provide evidence for not only homotypic-, but also heterotypic interactions among different sub-families, and even unconventional non-death domain fold interactions. As the number of potential protein associations among Death Domain Fold containing proteins expands and their influence on cellular responses increases, a challenging field for new investigations opens up. This review will focus on PYRIN domain-containing proteins and discuss the recent advances that provide strong evidence that PYRIN domain-mediated signal transduction has broad implications on cellular functions, including innate immunity, inflammation, differentiation, apoptosis, and cancer.
Keywords: Apoptosis, cancer, CARD domain, caspase activation, death domain fold, inflammation, interleukin-1, leucine rich region, NACHT domain, NF-κB
Current Protein & Peptide Science
Title: The PYRIN Domain in Signal Transduction
Volume: 8 Issue: 3
Author(s): Christian Stehlik
Affiliation:
Keywords: Apoptosis, cancer, CARD domain, caspase activation, death domain fold, inflammation, interleukin-1, leucine rich region, NACHT domain, NF-κB
Abstract: The Death Domain Fold superfamily of evolutionarily conserved protein-protein interaction domains consists of 4 subfamilies: the death domain, the death effector domain, the caspase recruitment domain, and the PYRIN domain. Interaction of Death Domain Fold containing proteins modulates the activity of several downstream effectors, such as caspases and transcription factors. Recent studies provide evidence for not only homotypic-, but also heterotypic interactions among different sub-families, and even unconventional non-death domain fold interactions. As the number of potential protein associations among Death Domain Fold containing proteins expands and their influence on cellular responses increases, a challenging field for new investigations opens up. This review will focus on PYRIN domain-containing proteins and discuss the recent advances that provide strong evidence that PYRIN domain-mediated signal transduction has broad implications on cellular functions, including innate immunity, inflammation, differentiation, apoptosis, and cancer.
Export Options
About this article
Cite this article as:
Stehlik Christian, The PYRIN Domain in Signal Transduction, Current Protein & Peptide Science 2007; 8 (3) . https://dx.doi.org/10.2174/138920307780831857
| DOI https://dx.doi.org/10.2174/138920307780831857 |
Print ISSN 1389-2037 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Peptide and Peptidomimetics: Structure, Assembly, and Applications
Peptides are fundamental biomolecules, imparting structural support, biochemical regulation, and potent pharmacological activity. The therapeutic significance of peptides and peptidomimetics was first demonstrated by the discovery of Insulin, leading to the development of clinically important agents such as Captopril, Semaglutide, and Goserelin, and the antibiotic Lariocidin. Progress in peptide chemistry ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclophilin D-mediated Mitochondrial Permeability Transition Regulates Mitochondrial
Function
Current Pharmaceutical Design Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors
Current Drug Targets Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics SAR131675 Receptor Tyrosine Kinase Inhibitor Induces Apoptosis through Bcl- 2/Bax/Cyto c Mitochondrial Pathway in Human Umbilical Vein Endothelial Cells
Anti-Cancer Agents in Medicinal Chemistry Bisubstrate Analogues as Glycosyltransferase Inhibitors
Current Topics in Medicinal Chemistry Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers
Current Pharmaceutical Biotechnology A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Editorial
Current Medicinal Chemistry Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Current Medicinal Chemistry New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer
Current Cancer Therapy Reviews Opportunities and Regulatory Challenges of Functional Foods and Nutraceuticals During COVID-19 Pandemic
Current Nutrition & Food Science Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Current Trends in Drug Delivery System of Curcumin and its Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Relation Between Helicobacter Pylori Infection and Gastroduodenal Diseases
Current Cancer Therapy Reviews Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology





